NASDAQ$GBIO

Generation Bio Co · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Reported second quarter 2024 financial results.

Generation Bio reported a net loss of $20.4 million, or $0.31 per share, for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $216.9 million as of June 30, 2024, expected to fund operations into the second half of 2027.

  • Cash, cash equivalents, and marketable securities were $216.9 million as of June 30, 2024.
  • Cash balance is expected to fund operations into 2H 2027.
  • Research and development expenses were $16.4 million for the quarter ended June 30, 2024.
  • Net loss was $20.4 million, or $0.31 basic and diluted net loss per share, for the quarter ended June 30, 2024.

Headline financials

Total Revenue

$4.09M

Previous: $880K+364.9%
EPS

-$0.31

Previous: -$0.47+34.0%
Research and development expenses

$16.4M

No prior period
General and administrative expenses

$9.5M

No prior period
Capital Expenditures

-$1.93M

Previous: -$2.21M+12.5%
Free Cash Flow

-$55.2M

Previous: -$5.08M-986.3%
Net Income

-$20.4M

Previous: -$31.1M+34.2%
Operating Income

-$23.3M

Previous: -$33.9M+31.3%
R&D Expense

$15.1M

No prior period
Stock-Based Comp

$3.7M

Previous: $6.02M-38.6%

Revenue & EPS history

Generation Bio · Revenue · Quarterly

$4.09M

Q2 2024+364.9%vs Q2 2023
Beat estimate in 7 of 10 quarters(70%)
ActualEstimate

Revenue by segment

Generation Bio · $2.15M total across 1 segment · Q3 2023

  • Collaboration revenue
    $2.15M

Forward guidance

The company continues to believe that its cash, cash equivalents, and marketable securities will fund its operating expenses and capital expenditures into the second half of 2027.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+3.8%

Avg return

Earnings day

+5.9%

Avg return

5 days after

+8.6%

Avg return

30 days after

43%

10 / 23 earnings

Positive

+61.7%

Q2 2025

Best reaction

-19.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025-3.3%+11.0%+2.7%
Q2 2025+61.7%+62.0%+46.9%
Q1 2025+4.5%+0.4%+4.0%
Q4 2024-3.7%-14.3%-9.5%
Q3 2024+8.7%-0.5%-40.8%
Q2 2024-2.0%-3.7%-10.2%
Q1 2024+18.4%+16.4%+1.9%
Q4 2023+3.1%+11.5%+39.4%
Q3 2023-1.7%+7.7%+46.2%
Q2 2023-5.3%-7.0%+6.8%
Q1 2023-5.0%-2.7%+0.4%
Q4 2022-8.4%-10.0%+15.5%
Q3 2022+12.2%
Q2 2022+7.7%
Q1 2022-19.7%
Q4 2021+21.1%
Q3 2021-1.5%
Q2 2021-6.2%
Q1 2021+0.3%
Q4 2020-0.9%
Q3 2020+8.5%
Q4 2019-0.5%
Q2 2020-0.5%
Q1 2020
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro